Monsanto Invests $1.5 Million Into Tekmira, The Company Making The Ebola Virus Cure

Fact checked

Monsanto. The company alone seems to have become the new business “boogie man” over the years with what has been reported about them. Here on The Inquisitr, we reported numerous times on this company, and most of them are not good at all. This includes Roundup Ready being linked to kidney disease, as well as what their GMO wheat has done for Kansas farmers. Despite their reported travesties, Hillary Clinton is a staunch supporter of their projects.

There are more reports going against Monsanto, but from what we have showed, would it be wise to have the company handle the production of the cure for the new scare virus, Ebola? For those who said no, unfortunate news is on your way. Monsanto has now invested $1.5 million into Tekmira, the company in charge of making a cure or vaccine for the Ebola virus.

According to an article by Yahoo Finance, Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced they received a $1.5 million milestone payment from Monsanto following the completion of specified program developments. The development milestone is part of the research program under the Option Agreement Tekmira signed with the agricultural company, which was announced on January 13, 2014. The agreement relates to Tekmira’s proprietary delivery technology and intellectual property for use in agricultural applications. Potential value of the transaction could reach up to $86.2 million.

However, critics of Monsanto, which includes Now The End Begins, are not happy about this. Once again, Tekmira has been working on the serum to treat Ebola. It’s trial was placed on hold while executives gathered information about how the drug works in the body per the request of the FDA.

The report continues in great detail on Inquisiter.com

5 Comments

Leave a Reply

Your email address will not be published.




This site uses Akismet to reduce spam. Learn how your comment data is processed.